Introduction: Although KRAS mutations in NSCLC have been considered mutually exclusive driver mutations for a long time, there is now growing evidence that KRASmutated NSCLC represents a genetically heterogeneous subgroup. We sought to determine genetic heterogeneity with respect to cancer-related co-mutations and their correlation with different KRAS mutation subtypes.
Introduction
Activating mutations in KRAS impairing guanosine triphosphatase activity are well known to play a pivotal role in oncogenic transformation. [1] [2] [3] About 30% of patients with NSCLC harbor somatic KRAS mutations 4, 5 and have a worse prognosis than do other patients with NSCLC. [6] [7] [8] Unlike for patients with NSCLC who harbor activating genetic aberrations in EGFR, [9] [10] [11] , ALK receptor tyrosine kinase gene (ALK), 12 or ROS1, 13 developments in targeted therapies have not yet led to an improved prognosis for KRAS-mutated patients. Thus, for patients with stage IV disease who are harboring KRAS mutations, standard chemotherapy has remained the criterion standard for more than three decades and has just recently been replaced by immunotherapy in a defined patient subgroup. 14 There is growing evidence for genetic heterogeneity of KRAS-mutated NSCLC. 15 Kinase inhibitors targeting molecules downstream of KRAS-like MEK inhibitors have shown modest efficacy, with response rates of 11% for selumetinib 16 and 12% for trametinib. 17 Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models. 19, 20 KRAS mutations occur both clonally and subclonally in human cancer, arguing against a unique presentation as "truncal" mutations. 21 In an analysis of cohorts with KRAS-mutated lung cancer that differed in clinical stage and preceding therapy, three major subgroups could be defined on the basis of RNA expression patterns and correlated with different patterns of co-occurring mutations in transformationassociated genes. 22 In addition, different KRAS proteins have been described as exerting different effects on transformation of downstream signal transduction pathways. 23 Recent work has revealed co-occurring kelch like ECH associated protein 1 gene (KEAP1)/ nuclear factor erythroid 2, like 2 gene (NFE2L2) mutations as an independent negative prognostic factor regarding survival and response to platinum-based chemotherapy 15, 24 and leading to dependence on glutaminolysis, whereas co-occurrence of serine/threonine kinase 11 deficiency promotes activation of proinflammatory cytokine production. 25 For the G12C mutation, specific inhibitors have shown preclinical activity and are under clinical evaluation. 26 Further therapeutic considerations might arise from the finding that co-mutations of KRAS and tumor protein p53 gene (TP53) are correlated with expression of programmed death ligand 1 in NSCLC, 27, 28 suggesting that these tumors might be predictive for antiprogrammed death 1/programmed death ligand 1 immunotherapy. Finally, KRAS mutations have also been described to co-occur with other potentially actionable mutations. For instance, the co-occurrence of KRAS mutations and MNNG HOS Transforming gene (MET) amplifications has been described in therapy-naive NSCLC. 29 Also, an additional KRAS mutation could be detected in a patient with activating EGFR mutation, leading to acquired resistance to third-generation EGFR tyrosine kinase inhibitors. 30 Nevertheless, a systematic analysis of co-occurring mutations in a large patient cohort is still lacking.
We here present next-generation sequencing (NGS) analysis of 1078 patients with NSCLC harboring KRAS mutations. Using a panel of 14 different transformationassociated genes, we analyzed the frequency and type of co-occurring mutations and their association with KRAS mutation subtypes. As our initial panel did not cover genes such as KEAP1, NFE2L2, or serine/threonine kinase 11 gene (STK11), we performed NGS using a different panel with 14 additional genes, including the aforementioned, in 101 patients. In a subset of patients, fluorescence in situ hybridization (FISH) of six further gene fusions or amplifications was conducted. Finally, we performed wholeexome sequencing (WES) in two patients to describe the evolutionary background exemplarily.
Patients and Methods

Patients
Tissue samples from 4507 patients with NSCLC that were sent consecutively to the central diagnostics platform of Network Genomic Medicine in Cologne, Germany, were routinely analyzed between August 2013 and May 2015 (Supplement 1). All patients gave written informed consent. No preselection of patients was performed. The study was conducted in accordance with local ethical guidelines and was reviewed by the institutional ethics committee.
Samples and Immunohistochemistry
Formalin-fixed, paraffin-embedded samples that were not necessarily derived from lung tissue of patients in whom NSCLC had been diagnosed were provided by Network Genomic Medicine collaborators. For each sample, at least one tumor area was chosen. Multiple tumor areas were chosen if one tumor area was not sufficient. NGS was performed only if more than 10% of the tumor cells were available. All primary diagnoses were done per the current WHO classification by experienced pathologists (R. B. and A. S.). Additional immunohistochemical stainings (cytokeratin 5/6, cytokeratin7, p40, and thyroid transcription factor 1) were performed to corroborate the diagnosis. 31 
NGS
All samples were analyzed with a validated gene panel 32 
FISH
MET, ERBB2, and FGFR1 were tested for amplification and classified as reported. 29, 33 ALK, ROS1, and RET were tested for rearrangement by break-apart FISH. 34, 35 FISH was performed according to local screening algorithms: FGFR1 screening was performed for squamous cell carcinoma (SqCC) routinely. Starting in June 2014, MET amplification was determined in all patients with the adenocarcinoma (ADC) subtype of NSCLC. ERBB2, RET, ROS1, and ALK were analyzed only in patients with unknown or wild-type KRAS status and not in patients with known KRAS mutation (see Supplement 1).
Evaluation of Detected Mutations
The detected mutations were analyzed by following a published workflow. 36 Intronic variants and silent mutations were identified and excluded from the results by using an in-house pipeline 37 (Supplement 2 and see also Supplement 1).
Clinical Characteristics
We assessed age, sex, tumor stage at diagnosis, smoking status (never-smoker, former smoker, or active smoker), smoking quantity (pack-years), overall survival (OS), and therapy when possible. Survival was calculated by using Kaplan-Meier methods (see Supplement 1) . Association between categorical variables was assessed by using chi-square tests or Fisher's exact tests, if appropriate.
WES and Clonality Analysis
For details, see Supplement 1. In brief, allelic fractions of somatic mutations were corrected for purity and copy number changes to determine cancer cell fractions. Next, the distribution of cancer cell fractions was searched for distinct subpopulations by using a nonparametric method to deconvolute the noise in the cancer cell fractions.
Results
Patients with KRAS Mutations
KRAS Status. On the basis of 4507 samples analyzed, 1207 patients (26.8%) harbored a KRAS mutation and 1078 patients (89.3%) were eligible for analysis (Fig. 1A) . The dropouts were due to false histopathological diagnosis, low amount of tumor available, or poor DNA quality. The most frequent KRAS mutation, G12C, was present in 449 samples (41.7%) (Fig. 1B) . G12X mutations were by far the most common mutations (n ¼ Figure 1 . (A) Analytical workflow of this study. (B) Pie chart visualizing the relative frequencies of different KRAS mutation subtypes among the cohort. (C) Frequency of co-occurring aberrations in KRAS-mutated patients (inrelation to the numbers analyzed). Only prevalences of at least 5% are shown. AKT1, AKT/serine threonine kinase 1 gene; ALK, ALK receptor tyrosine kinase gene; amp, amplification; ATM, ATM serine/threonine kinase gene; CI, confidence interval; CTNNB1, catenin beta 1 gene; DDR2, discoidin domain receptor tyrosine kinase 2 gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; ERBB4, erb-b2 receptor tyrosine kinase 4 gene; FGFR1, fibroblast growth factor receptor 1 gene; FGFR2, fibroblast growth factor receptor 2 gene; FISH, fluorescence in situ hybridization; HER2, synonym of ERBB2; KDR, kinase insert domain receptor gene; KEAP1, kelch like ECH associated protein 1 gene; KIT, KIT proto-oncogene receptor tyrosine kinase gene; MAP2K1, mitogen-activated protein kinase kinase 1 gene; MET, MNNG HOST Transforming gene; mut, mutation; NFE2L2, nuclear factor erythroid 2, like 2 gene; NGS, next-generation sequencing; PDGFR, previous symbol of PDGFRB (platelet derived growth factor receptor beta gene); PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; PIK3CG, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma gene; PTEN, phosphatase and tensin homolog gene; RET, ret protooncogene gene; SMARCA4, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 gene; STK11, serine/threonine kinase 11 gene; TP53, tumor protein p53 gene. Of the 101 samples analyzed with the extended NGS panel including genes that had already been shown to co-occur frequently with KRAS mutations such as KEAP1 or STK11, 77 (76.2%) had additional mutations. All mutations detected with the initial approach were able to be confirmed ( Figure 1C and Table 2 ).
Impact of Clinical Parameters on the Presence of Additional Mutations. In multiple logistic regression analyses using the initial gene panel and including smoking status (qualitatively and quantitatively), age, sex, stage, and histologic subtype, only tumor stage was significantly associated with the co-occurrence of additional mutations (data not shown).
Frequency of Targetable Co-mutations. Of the 13 patients with EGFR mutation (1.2%), two harbored L858R (one with an additional T790M de novo), one an exon 19delins, one G719C, one S768I, and one an E709* nonsense mutation. Another patient had D770_V774dup, whereas the remaining were not curated. Most of the 35 patients (3.2%) with PIK3CA mutation had mutations affecting exon 9 (n ¼ 31), with the remaining representing H1047X (exon 20) mutations. Of the 14 patients (1.3%) harboring BRAF mutations, one had V600E, one G596V, beside G464V (n ¼ 2) and G469V (n ¼ 3). There were no targetable mutations in DDR2, MET, ERBB2, or ALK (see Supplement 2) .
Of the 606 samples analyzed by FISH for MET amplification, 93 (15.4%) were amplified. Of these, 60 were low-level and 30 were high-level amplifications. The samples from nine of the 65 patients (13.8%) with known ERBB2 amplification status were amplified, all of them from patients with ADC. FGFR1 amplifications were found in three (4.9%) of the 61 analyzed samples. Two of these patients had SqCC, and one had mixed SqCC/SCLC. No rearrangements were found in ALK, ROS1 and RET.
Co-occurring Mutations Depending on KRAS Subtype. We calculated the relative frequencies of co-occurring aberrations in the most common KRAS subtypes and compared our results with the averages for the whole KRAS-mutated cohort (only mutations that occurred in more than 1% [ Fig. 2A]) . Patients with G12C harbored all detected ERBB2 amplifications (p ¼ 0.002) as well as all detected ERBB4 mutations (p ¼ 0.025), whereas PTEN and BRAF mutations were less common than in the total cohort. In contrast, G12V and G13X mutations frequently co-occurred with PTEN mutations (p ¼ 0.008). Patients with G12D showed a high prevalence of co-occurring PDGFRA mutations (p ¼ 0.031) and lack of EGFR mutations, as well as G12A and G13X. Patients with Q61X mutations had no co-occurring PTEN mutations but showed the highest prevalence of BRAF mutations (not significant). G12A mutations had the highest prevalence in patients with SqCC (7.5%) and co- April 2019 Heterogeneity of KRAS-mutated NSCLCoccurred more frequently with CTNNB1 mutations and FGFR1 amplifications, albeit not significantly owing to low patient numbers (Fig. 2B) . (Fig. 3A) . We further focused on patients with stage IV disease, for whom the different KRAS mutations did not show differences in mOS (see Fig. 3B and Supplement 3 for details on the whole cohort). With use of our new panel, mOS did not differ significantly between patients in stage IV without additional mutation and those with co-occurring mutation WES and Clonality Analyses. To gain some insight into the intratumor heterogeneity of KRAS-mutated ADC with co-occurring PIK3CA mutations, we reconstructed subclonal populations of two cases in which WES was performed ( Fig. 4A and B) . In both cases, the E545K mutations in PIK3CA were subclonal, whereas one KRAS mutation was clonal (G12C [sample C13-39572]) and the other was present in the same subclonal population that harbored the PIK3CA mutation (Q61L [sample C12-3094] ). Furthermore, sample C13-39572, which contained a total of 1197 mutations, showed a particularly high mutational burden, but most of these mutations (90.2%) were found to be subclonal. In addition, a TP53 mutation together with subclonal loss was detected in a minor subclone, thus showing a biallelic deactivation of TP53 in about 59% of the tumor cells. These two examples suggest that mutations in KRAS, and similarly in TP53 and PIK3CA, may be subclonal and therefore represent late events in tumor evolution in a fraction of NSCLC tumors.
Impact of KRAS
To get an overview of mutational load in different KRAS subtypes, we analyzed the data sets of The Tumor Cancer Genome Atlas (see Supplement 3).
Discussion
Mutations in KRAS represent the longest-known and most frequent oncogenic mutations in NSCLC and are still considered undruggable. 38 According to recent molecular findings, there is growing evidence that KRASmutated lung cancer does not represent a homogeneous NSCLC subgroup. 15, 22, 39, 40 We have here presented what to our knowledge is the largest cohort of patients with KRAS-mutated NSCLC to have been described so far and been systematically analyzed for genetic heterogeneity by the assessment of co-occurring mutations in transformation-associated pathways. Our evaluation of 1078 KRAS-mutated patients analyzed in routine diagnostics with NGS supplemented by FISH analyses in a subset of these patients shows that co-occurring genetic aberrations can be found frequently, with a significantly higher prevalence in patients with metastasis.
The clinical relevance of co-occurring mutations remains to be established. However, for several co-mutations, specific targeted approaches are in clinical evaluation (e.g., for MET, 41 ERBB2, 42 and FGFR1 amplifications, 43 as well as for PIK3CA mutations) and may become systemic treatment options in the near future. Because targeted approaches are also evaluated against mutated KRAS, the hierarchy or cooperation of co-occurring drivers in relation to KRAS remains to be elucidated. Co-occurrence of amplified MET and mutated KRAS, for example, might influence the therapeutic activity of mesenchymal-epithelial transition tyrosine kinase inhibitors, as well as that of KRAS inhibitors. The same holds true for other targetable co-mutations. One limitation of our study concerning an accurate determination of the frequency of targetable comutations is that the FISH analysis for assessment of amplification was done only in a subset of the total cohort of patients with KRAS mutation. Nevertheless, our results point to the necessity of integrating the knowledge of comutations into clinical trials (e.g., by stratification according to potentially relevant co-mutation or by testing of combination therapy approaches). The present data not only suggest that KRAS-mutated NSCLC should no longer be understood and managed as a homogenous genetic subgroup but also underline the fact that routine testing for co-occurring mutations might already now be of therapeutic relevance in a substantial proportion of KRASmutated patients. Besides the amplifications, the response to chemotherapy, the survival differences, and (albeit with a very low frequency of less than 1%) even "classical" activating EGFR del19 or L858R and BRAF V600E mutations were also detected. Increasing use of NGS will detect new mutations whose biological significance must still be elucidated. This holds true for many of the co-occurring mutations in our cohort. Another limitation of our study, namely, the short follow-up, was anticipated in advance, as we set out this study to gain an overview on KRAS heterogeneity in "allcomers" and in real-time. A second clear limitation is the restricted number of genes in our 14-gene NGS panel, which was established for routine diagnostics in 2013 to widen targetable therapy in NSCLC, although so far, not all the genes analyzed have been proved to be targetable and new targetable genes such as neurotrophic receptor tyrosine kinase 1 gene (NTRK1), neurotrophic receptor tyrosine kinase 2 gene (NTRK2), and neurotrophic receptor tyrosine kinase 3 gene (NTRK3) were not included at that time. As genes with a reported effect on co-occurring KRAS mutations (such as KEAP1, NFE2L2, and STK11 15, 25, 44 ) were not included in our panel, we set up a new NGS panel of 22 genes that included all of these genes and reanalyzed samples from 101 patients. Within this analysis, the prevalence of co-occurring mutations was substantially higher than in our initial panel, demonstrating the need for advanced panels in routine setting. The relatively high prevalence of STK11 or KEAP1 mutations and their impact on survival might easily have remained unnoticed and unreported had only the initial panel been used. The In sample C13-39572, the KRAS mutation (G12C) was clonal, whereas the PIK3CA E545K mutation was subclonal. This case had a total of 1197 mutations, but 90.2% of these mutations were subclonal. A tumor protein p53 gene (TP53) mutation (R248L) together with subclonal loss was detected in a minor subclone, thus showing a biallelic deactivation of TP53 in about 59% of the tumor cells. (B) In C12-3094, the KRAS Q61L mutation was present in the same subclonal population that harbors the PIK3CA mutation (E545K).
co-occurrence of ROS1 mutations and their preliminarily noted impact on survival needs further evaluation. KRAS mutations can occur both clonally or subclonally in NSCLC, 21 and recent efforts have tried to connect this evolutionary heterogeneity with treatment approaches. 45 Exemplarily, we performed WES in two patients to analyze the clonality of KRAS and cooccurring mutations. In one patient, we found a clonal KRAS mutation, and in the other, we found a subclonal KRAS mutation. Other drivers such as PIK3CA and TP53 were found to be subclonal in these two cases, suggesting that in a fraction of NSCLC cases strong oncogenic events may develop late in tumor evolution.
In summary, our data show that NSCLC comprises a strongly heterogeneous group on the genomic level and that co-occurring mutations, with both with alreadyproven and still-unproven therapeutic relevance, are present in a substantial amount of these patients. Our data strongly suggest the need for consideration of the heterogeneity of KRAS mutations regarding mutation type itself and co-occurring mutations in the development of treatment approaches with specific KRAS inhibitors, as well as with approaches targeting oncogenic drivers downstream KRAS or using immune checkpoint inhibitors.
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